Literature DB >> 27088866

Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study.

Chaoqun Liu1, Yuan Zhang2, Ding Ding1, Xinrui Li1, Yunou Yang1, Qing Li1, Yuanzhu Zheng1, Dongliang Wang3, Wenhua Ling4.   

Abstract

BACKGROUND: Although diminished cholesterol efflux capacity is positively related with prevalent coronary artery disease, its prognostic value for incident cardiovascular events remains a topic of debate. This work aims to investigate the association between cholesterol efflux capacity and all-cause and cardiovascular mortality in patients with coronary artery disease. METHODS AND
RESULTS: We measured cholesterol efflux capacity at baseline in 1737 patients with coronary artery disease from the Guangdong Coronary Artery Disease Cohort. During 6645 person-years of follow-up, 166 deaths were registered, 122 of which were caused by cardiovascular diseases. After multivariate adjustment for factors related to cardiovascular diseases, the hazard ratios of cholesterol efflux capacity in the fourth quartile compared with those in the bottom quartile were 0.24 (95% confidence intervals 0.13-0.44) for all-cause mortality (P < 0.001), and 0.17 (95% confidence intervals 0.08-0.39) for cardiovascular mortality (P < 0.001). Adding cholesterol efflux capacity to a model containing traditional cardiovascular risk factors significantly increases its discriminatory power and predictive ability for all-cause (area under receiver operating characteristic curve 0.79 versus 0.76, P = 0.001; net reclassification improvement 14.5%, P = 0.001; integrated discrimination improvement 0.016, P < 0.001) and cardiovascular (area under receiver operating characteristic curve 0.81 versus 0.78, P = 0.001; net reclassification improvement 18.4%, P < 0.001; integrated discrimination improvement 0.015, P < 0.001) death, respectively.
CONCLUSIONS: Cholesterol efflux capacity may serve as an independent measure for predicting all-cause and cardiovascular mortality in patients with coronary artery disease.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  All-cause mortality; Cardiovascular mortality; Cholesterol efflux capacity; Coronary artery disease; High-density lipoprotein

Mesh:

Substances:

Year:  2015        PMID: 27088866     DOI: 10.1016/j.atherosclerosis.2015.10.111

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

1.  Changes in High-Density Lipoprotein Cholesterol Efflux Capacity After Bariatric Surgery Are Procedure Dependent.

Authors:  Sean P Heffron; Bing-Xue Lin; Manish Parikh; Bianca Scolaro; Steven J Adelman; Heidi L Collins; Jeffrey S Berger; Edward A Fisher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-21       Impact factor: 8.311

2.  A new method for measuring cholesterol efflux capacity uses stable isotope-labeled, not radioactive-labeled, cholesterol.

Authors:  Tomo Shimizu; Osamu Miyazaki; Takeo Iwamoto; Tomoyuki Usui; Ryo Sato; Chika Hiraishi; Hiroshi Yoshida
Journal:  J Lipid Res       Date:  2019-08-27       Impact factor: 5.922

3.  Molecular Patterns of Extreme and Persistent Cholesterol Efflux Capacity.

Authors:  Ayea El-Ghazali; Sneha Deodhar; Suzanne Saldanha; Brooke Smyth; Mark Izbrand; Anamika Gangwar; Mandana Pahlavani; Anand Rohatgi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-08-26       Impact factor: 10.514

4.  Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles.

Authors:  Wen Guo; Karol M Pencina; Jeremy D Furtado; Frank M Sacks; Tomas Vaisar; Ming Cheng; Allan D Sniderman; Stephanie T Page; Shalender Bhasin
Journal:  J Endocr Soc       Date:  2022-06-28

5.  Reverse Cholesterol Transport and Atherosclerosis.

Authors:  Anand Rohatgi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

6.  Cholesterol Efflux and Collateral Circulation in Chronic Total Coronary Occlusion: Effect-Circ Study.

Authors:  Seonhwa Lee; Jung Mi Park; Soo-Jin Ann; Moonjong Kang; Eun Jeong Cheon; Dan Bi An; Yu Ri Choi; Chan Joo Lee; Jaewon Oh; Sungha Park; Seok-Min Kang; Sang-Hak Lee
Journal:  J Am Heart Assoc       Date:  2021-02-26       Impact factor: 5.501

Review 7.  High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.

Authors:  Chengfeng Qiu; Xiang Zhao; Quan Zhou; Zhen Zhang
Journal:  Lipids Health Dis       Date:  2017-11-10       Impact factor: 3.876

8.  Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease.

Authors:  Guisong Wang; Anna Vachaparampil Mathew; Haiyi Yu; Lei Li; Liyun He; Wei Gao; Xiaodan Liu; Yanhong Guo; Jaeman Byun; Jifeng Zhang; Y Eugene Chen; Subramaniam Pennathur
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

9.  CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.

Authors:  Andreas Gille; Denise D'Andrea; Michael A Tortorici; Gunter Hartel; Samuel D Wright
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02-08       Impact factor: 8.311

10.  Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.

Authors:  Bo Zheng; Danielle Duffy; Pierluigi Tricoci; Helen Kastrissios; Marc Pfister; Samuel D Wright; Andreas Gille; Michael A Tortorici
Journal:  Br J Clin Pharmacol       Date:  2020-12-23       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.